Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Nasdaq Biotechnology Ishares ETF (NQ: IBB )

136.10 +1.26 (+0.93%)
Official Closing Price Updated: 4:15 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Nasdaq Biotechnology Ishares ETF

< Previous 1 2 3 4 5 6 7 8 9
...
24 25 Next >
Women's Reproductive Rights: US Court Preserves Access To Abortion Pill For Now, But With Tighter Rules
A U.S. federal appeals court has temporarily blocked a decision by a Texas judge to halt the FDA's approval of a widely used abortion drug. 
Via Benzinga
Trillions In Biotech Stock Gains Trace Back To This Financier
Frank did not grow up as son of a Wall Street banker. He began as the consummate outsider. 
Via Investor's Business Daily
New York and California Prepare For Potential Mifepristone Ban In Texas With Stockpiling Of Alternative Abortion Medications
New York and California are stockpiling an alternative abortion medication in case a Texas judge's order suspending the FDA approval of the primary drug, mifepristone, goes into effect later this... 
Via Benzinga
Attorney Generals of Over 20 States Sound Alarm Over Suspension Of Abortion Med Approval: "Devastating Risks" Ahead
In a new court filing, the Democratic attorneys general for 23 U.S. states have reportedly warned that a federal judge's decision to suspend the FDA's approval of mifepristone "presents devastating... 
Via Benzinga
April Is Busting Out For Healthcare And Biotech
Last week was a good week for healthcare stocks and most large cap biopharmaceutical stocks resumed an upward trend. 
Via Talk Markets
FDA Withdraws Lone Premature Birth Drug Makena Over Lack of Proven Benefits
Via Benzinga
AbbVie, Thermo Fisher Scientific And A Must-Watch Biotech ETF: CNBC's 'Final Trades'
On CNBC’s "Halftime Report Final Trades," Bryn Talkington of Requisite Capital Management said she is sticking with AbbVie Inc. (NYSE: ABBV), which has a 7.3% free cash flow yiel 
Via Benzinga
Large Cap Biopharmaceuticals Q1 2023: In This Bullish Run Biotech Lags
It was very difficult to make money in Q1 trading healthcare or biotech ETFs because of the sharp rally in other sectors. Nonetheless, there were two big winners. 
Via Talk Markets
Biotech And Life Science Trades: Q1 2023 Performance By The Numbers
Despite a strong month and a great finish to the quarter, many traders remain cautious about the market. It’s been a volatile time after the collapse of Silicon Valley Bank, but the first quarter of... 
Via Talk Markets
Market - What About The China/Russian BrahFest?
Looking at the S&P 500 chart on a weekly timeframe, SPY needs a weekly close over the 50-week moving average at 395-396. 
Via Talk Markets
US Judge Weighs Nationwide Ban On Abortion Pills
U.S. District Judge Matthew Kacsmaryk questioned President Joe Biden's administration lawyers on whether the federal regulatory approval of the abortion pill mifepristone was proper. The judge is... 
Via Benzinga
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector
To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy. 
Via InvestorPlace
Silicon Valley Bank Meltdown Hits Healthcare Sector As Well
The Federal Deposit Insurance Corporation (FDIC) closed Silicon Valley Bank, the banking arm of SVB Financial Group (NASDAQ: 
Via Benzinga
Hefty Listing Price Of New Drugs For Cancer, Rare Diseases Put Pressure On Annual Hike For Older Drugs
New branded medicines are coming to market with ever-higher price tags as soon as the first day. Amgen Inc's (NASDAQ: AMGN) lung cancer treatment, Lumakras, carried a hefty price tag of $17,900 per... 
Via Benzinga
FDA Seeks 10% Increase In Biden's FY 2024 Budget, Proposes Enhancing Regulatory Authorities
Via Benzinga
Covis Pharma To Withdraw Only FDA-Approved Treatment To Prevent Preterm Births
Via Benzinga
Health Care ETFs Have Lost In The Last Month - These Top Pharma Stocks Are The Reason
Via Benzinga
Retail And Regional Banks Will Call The Shots
The 23-month moving average or a 2-year business cycle is particularly important this year after a big up then down year-looms large. 
Via Talk Markets
The Economic Modern Family Ready To Howl?
As we ended the trading week, there were a few other “worms” that appeared in the market soil. They too seemed to awaken from hibernation as the indices’ prices rose. Are the components of the Economic... 
Via Talk Markets
Bullish Reversals
Agricultural commodities have fallen a lot lately. Food supply and shortages remain a concern going into the spring and summer growing seasons. 
Via Talk Markets
FDA Takes Action To Restrict Unlawful Import Of Animal Tranquilizer 'Tranq' Or ''Zombie Drug'
Via Benzinga
Century Aluminum Pops Up As Bullish
Given the recent sell-off in aluminum, copper, and steel, industrial metals remain overall outperformers. 
Via Talk Markets
Stock Market Forecast: Stocks May Drop Further As Rates Rise
This week will be full of economic insights, but the big data will be the ISM manufacturing and services indexes. However, I think these two reports are unlikely to do much to reverse the current trend... 
Via Talk Markets
No Landing - Sugar Coated Words For Stagflation?
SPX failed the 23-month moving average or 2-year business cycle, which if clears, signals a softer landing. Yet, it held the pivotal 3900 ahead of the Fed, signaling a no landing. 
Via Talk Markets
Is The Whole Country Buying Teslas And Eating At Wingstop?
XRT is making lower highs each of the last 3 weeks but also has found a basis of support at 68.00. 
Via Talk Markets
Tuesday Talk: My Sweet CPI
The street is hoping for sweet January CPI data today and that anticipation pushed stocks higher on Monday. 
Via Talk Markets
Large-Cap Biopharmaceuticals: Bearish Sentiment Curbs Buyers
Large cap biopharma stocks are off their highs despite reasonable valuations plus dividends. 
Via Talk Markets
ARK Invest: The 7 Words That Explain Why Wall Street Can’t Stand Cathie Wood
Why does Wall Street hate Cathie Wood and her ARKK ETF? Seven words show how her focus on innovation divides investors. 
Via InvestorPlace
2-Year Business Cycles Matter In Commodities
Gold is above the 23-month MA and the 2-year business cycle. 
Via Talk Markets
2-Year Business Cycles Matter In This Market
In October, IWM held the 80-month and got us believing that a recession would be averted. Now, the market literally hangs in the balance between a longer-term and a shorter-term business cycle. 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 9
...
24 25 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.